Enzymatic therapy for celiac

01Overview and value chain

Markers: [EC: EU/US drug-development regulatory pathway for celiac disease therapeutics | OECD: Bio-pharmaceuticals | Regulator: EMA (EU), FDA (USA)]

Enzymatic therapy for celiac disease applies engineered enzymes and enzyme-targeting inhibitors to protect celiac patients from the autoimmune intestinal damage triggered by dietary gluten, as a pharmaceutical complement to the lifelong gluten-free diet that remains the only established treatment. Researchers at the University of Barcelona and the Institut de Biologia Molecular de Barcelona (IBMB-CSIC) designed “celiacase,” a recombinant enzyme active at gastric pH that works synergistically with pepsin to degrade gluten immunogenic peptides — including the highly reactive 33-mer fragment from wheat alpha-gliadin — before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models; the molecule is patented and a spin-off is being formed to advance it toward clinical use. In Germany, Dr. Falk Pharma has funded university research on ZED1227, an oral inhibitor of transglutaminase 2 (TG2) — the enzyme that deamidates gluten peptides and triggers the celiac immune cascade — which in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose. On the commercial supplement side, DSM-Firmenich markets Tolerase G, an Aspergillus niger-derived prolyl endoprotease (AN-PEP) sold as a dietary-supplement ingredient to support digestion of incidental gluten exposure, though it lacks the same clinical-trial evidence base as the prescription-track candidates. In the US, Seattle’s PvP Biologics developed KumaMax, an oral enzyme designed to break down immune-reactive gluten in the stomach, under a 2016 deal in which Takeda committed $35 million in R&D funding plus an option to acquire PvP; the program advanced into Takeda’s pipeline as zamaglutenase (TAK-062), and industry reporting indicates its later-stage trial showed increased mucosal damage rather than protection, after which the program was discontinued.

The key directions of enzymatic therapy for celiac are:

1. Gastric-active gluten-degrading enzymes (Gastric-Active Gluten-Degrading Enzymes): engineered or recombinant proteases active at low stomach pH that degrade immunogenic gluten peptides before they reach the duodenum.
2. Transglutaminase-2 (TG2) inhibition (Transglutaminase-2 (TG2) Inhibition): small-molecule inhibitors blocking the enzyme that deamidates gluten peptides and triggers the autoimmune cascade, rather than degrading gluten itself.
3. Oral supplement-grade digestive enzymes (Oral Supplement-Grade Digestive Enzymes): commercially marketed enzyme blends intended to aid incidental gluten digestion, sold without the same clinical evidence bar as prescription-track therapeutics.
4. Staged biotech-to-pharma enzyme partnerships (Staged Biotech-to-Pharma Enzyme Partnerships): large pharmaceutical companies funding a smaller biotech’s engineered-enzyme platform through milestone-based option-to-acquire deals.

Sectoral value chain

[enzyme/inhibitor design] ──> [preclinical validation] ──> [clinical gluten-challenge trial] ──> [efficacy/safety evaluation]
                                                                              │
                                                                       (regulatory decision
                                                                        or program halt)
                                                                              │
                                                                              ▼
[patient use/sale] <─── [commercial/OTC formulation] <─────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Recombinant gastric-active proteases (Recombinant Gastric-Active Proteases): enzymes engineered for peak activity at gastric pH, synergizing with native pepsin to pre-digest immunogenic gluten fragments.
• Transglutaminase-2 inhibitor chemistry (Transglutaminase-2 Inhibitor Chemistry): small molecules blocking the deamidation step that increases gluten peptides’ affinity for HLA-DQ2/DQ8 antigen presentation.
• Prolyl endopeptidase supplementation (Prolyl Endopeptidase Supplementation): Aspergillus niger-derived AN-PEP enzymes marketed as digestive aids for incidental gluten exposure.

02US

The US contributed the original enzyme-engineering platform behind one of the most closely watched — and ultimately discontinued — programs in the field, developed by a small Seattle biotech before a major pharma partnership took over its clinical advancement.

Seattle-originated enzyme engineering, staged pharma option-to-acquire, later-stage program discontinuation

• PvP Biologics (Seattle) / Takeda: PvP Biologics developed KumaMax, an oral enzyme designed to break down immune-reactive gluten in the stomach; under a 2016 deal, Takeda committed $35 million in R&D funding with an option to acquire PvP on completion of defined milestones. The program advanced under Takeda as zamaglutenase (TAK-062) — reported to degrade 6 grams of gluten in Phase 1 — but industry reporting indicates a later trial stage showed increased mucosal damage (a falling villus-height-to-crypt-depth ratio) rather than protection, after which the program was discontinued.

03CN

Public information on a dedicated Chinese enzymatic-therapy-for-celiac originator was not confirmed with company-specific detail in this pass; Chinese-language coverage of the field consists of medical-education and market-report content on celiac disease and gluten-free products rather than a confirmed domestic drug-development originator.

no confirmed company-specific detail this pass, medical-education and gluten-free-market coverage only

• No confirmed company-specific detail this pass: the sources returned for this region were general medical-education content (disease mechanism explainers, a gluten-free product market report) rather than a source confirming a specific Chinese enzymatic-therapy-for-celiac originator.

04EU

The EU anchors both an academic gastric-enzyme discovery moving toward spin-off commercialization and a pharma-funded transglutaminase inhibitor already showing human clinical protection, alongside a long-established OTC digestive-enzyme ingredient business.

gastric-active enzyme spin-off formation, TG2-inhibitor clinical protection, established OTC AN-PEP ingredient

• University of Barcelona / IBMB-CSIC: designed “celiacase,” a recombinant enzyme active at gastric pH that degrades gluten immunogenic peptides — including the 33-mer fragment from wheat alpha-gliadin — synergistically with pepsin before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis in mouse models; the molecule is patented, with a spin-off being formed to advance clinical development.
• Dr. Falk Pharma: funded university research (Tampere University, University of Oulu) on ZED1227, an oral TG2 inhibitor that in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose, with the researchers cautioning it remains premature to call it a gluten-free-diet replacement.
• DSM-Firmenich: markets Tolerase G, an Aspergillus niger-derived prolyl endoprotease (AN-PEP) sold as a dietary-supplement ingredient supporting digestion of incidental gluten exposure, without the same clinical evidence base as the prescription-track candidates.

05Leading companies and research institutes

06Tech stack and innovations

The stack spans gastric-active enzyme engineering, enzyme-target inhibition and commercial OTC enzyme supplementation.

1. Gastric-active recombinant proteases (Gastric-Active Recombinant Proteases):
   • engineered proteins reach maximum activity at gastric pH (~2), working alongside native pepsin to degrade immunogenic gluten peptides before they reach the duodenum, then self-inactivating in the intestine.
   • case: the University of Barcelona/IBMB-CSIC’s celiacase reduced intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models.
2. TG2-inhibitor small-molecule chemistry (TG2-Inhibitor Small-Molecule Chemistry):
   • blocking transglutaminase 2 prevents the deamidation step that increases gluten peptides’ binding affinity to HLA-DQ2/DQ8, upstream of the immune cascade rather than degrading gluten directly.
   • case: Dr. Falk Pharma-funded ZED1227 protected patients from measurable mucosal damage and inflammation during a 6-week, 3g/day gluten challenge at 100mg daily.
3. Engineered oral gluten-degrading enzymes (Engineered Oral Gluten-Degrading Enzymes):
   • a recombinant enzyme engineered to break down immune-reactive gluten fragments in the stomach before intestinal exposure.
   • case: PvP Biologics/Takeda’s zamaglutenase (TAK-062) degraded 6 grams of gluten in a Phase 1 study, though a later trial stage reportedly showed worsened mucosal damage, illustrating the difficulty of ensuring degradation byproducts remain non-immunogenic at scale.

07Value chains and production pipelines

Industrial pipeline of enzyme/inhibitor development for celiac disease (EMA/FDA drug-development framework)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Enzyme/inhibitor design│ ───> │ 2. Preclinical validation │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Efficacy/safety eval.  │ <─── │ 3. Clinical gluten-challenge│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Commercial/OTC formul. │ ───> │ 6. Patient use/sale       │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Enzyme/inhibitor design

A recombinant enzyme or small-molecule inhibitor is engineered to target a specific step of gluten immunogenicity — direct peptide degradation or TG2 inhibition.

Stage 2: Preclinical validation

The candidate is tested in biochemical assays or animal models for gluten-degradation or TG2-inhibition activity, measuring markers such as intestinal atrophy, inflammation and antibody response.

Stage 3: Clinical gluten-challenge trial

Celiac patients on the candidate are exposed to a controlled daily gluten dose over a defined period, with a placebo arm for comparison.

Stage 4: Efficacy/safety evaluation

Histologic (villus-height-to-crypt-depth ratio), immunologic and symptom outcomes are compared against a defined clinical bar, leading either toward regulatory advancement or program discontinuation.

Stage 5: Commercial/OTC formulation (parallel track)

Independently of the prescription-drug pathway, an enzyme such as AN-PEP can be formulated and sold as a dietary-supplement ingredient without the same trial requirements.

Stage 6: Patient use/sale

The resulting prescription therapeutic (if approved) or OTC supplement reaches celiac patients as a complement to the gluten-free diet.